VivoSim Labs (FRA:4OR) Price-to-Tangible-Book: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4OR VivoSim Labs Inc FRA:4OR
33 GF Score
Price €3.49
GF Value €22.53
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs Price-to-Tangible-Book?

As of today (2026-08-14), VivoSim Labs's share price is €3.492. VivoSim Labs's Tangible Book per Share of Mar. 2026 for the quarter that ended in Mar. 2026 was €-0.33. Hence, VivoSim Labs's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for VivoSim Labs's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, VivoSim Labs's highest Price to Tangible Book Ratio was 5.34. The lowest was 0.41. And the median was 2.13.

FRA:4OR's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 3.25
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, VivoSim Labs's share price is €3.492. VivoSim Labs's Book Value per Sharefor the quarter that ended in Mar. 2026 was €-0.33. Hence, VivoSim Labs's P/B Ratio of today is .

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

VivoSim Labs Price-to-Tangible-Book Related Terms

VivoSim Labs Price-to-Tangible-Book Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Price-to-Tangible-Book Chart

VivoSim Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 1.26 2.84 0.68 0.00

VivoSim Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 1.10 1.51 2.40 0.00

FRA:4OR vs MTNB, HEPA, CLSDQ: Price-to-Tangible-Book Comparison

For the Biotechnology subindustry, VivoSim Labs's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VivoSim Labs Price-to-Tangible-Book vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Price-to-Tangible-Book falls into.


FRA:4OR
33GF Score
VivoSim Labs Inc FRA:4OR
Price-to-Tangible-Book is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Price-to-Tangible-Book Calculation

VivoSim Labs's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2026 )
=3.492/-0.328
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 84.5% below its estimated GF Value™ of €22.53.

Key valuation signals for FRA:4OR:

  • Price-to-Tangible-Book:
  • GF Value™: €22.53 vs. price of €3.49 (84.5% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score

Get the complete analysis for FRA:4OR

Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€22.53
GF Value